Colorectal Cancer Clinical Trial
Official title:
Colorectal Cancer Testing in Swiss Primary Care: A Pilot Pragmatic Cluster Randomized Controlled Trial in Quality Circles of Physicians
In Switzerland, colorectal cancer (CRC) is the third most common cause of death from cancer
with 1600 persons dying from CRC each year. CRC screening can prevent most of these deaths.
If screening begins at age 50, with either colonoscopy or faecal immunological test (FIT),
the absolute risk of dying from CRC at age 80 can be cut in half. The choice between CRC
screening methods can be seen as preference-sensitive condition. FIT can detect CRC at a
similar rate as colonoscopy, but cannot detect as many polyps and advanced polyps as
colonoscopies. Colonoscopy would seem the best choice for patients who want to reduce their
risk of developing CRC or dying from CRC, but colonoscopy is an invasive procedure with rare
but serious adverse effects. Patients who choose FIT do not need to prepare their bowels, or
take a day off, but instead sample their own stool at home and mail the test to the
laboratory. Offering the choice of test might also increase overall screening rates.
Guidelines from the US Services Task Force (USPSTF) suggest shared decision making as a
method for increasing adherence to screening and elicit patients' preferences for screening
options.
Family physicians are recognized as the most trusted professional to discuss CRC screening in
Switzerland. However, many primary care physicians (PCPs) appear to prefer colonoscopy over
FIT, and the preferred method seems to vary widely between regions. Physician preferences and
local medical culture likely determine these choices more than patient preference. It may be
possible to reduce the number of PCPs who prescribe only one screening method by encouraging
them to diagnose their patient's preferences for screening method. In Switzerland, training
PCPs with educational support and decision aids increased the number who intend to prescribe
both screening modalities in equal proportions (prescription of both colonoscopy and FIT in
equal proportions).
To implement the intervention and determine how and if it changes PCP practice over time, the
study will be conducted in quality circles (QCs) of PCPs. QCs are usually groups of 6 to 12
PCPs who meet regularly to reflect on their practice. QCs are a multifaceted, step-based
intervention for quality improvement that has gained international traction because they can
foster long-lasting behaviour change. In Switzerland, 80% of all PCPs attend QC regularly.
Through QCs following the principles of Plan-Do-Check-Act (PDCA) quality improvement cycles,
PCPs can find ways to lower structural barriers to screening, assess their screening
practices, and give each other feedback.
The study hypothesizes that providing PCPs with evidence summaries on CRC screening, decision
aids for patients, and sample FIT tests will increase the number of patients screened for
CRC, better balance the selection of screening methods (colonoscopy vs. FIT), increase the
proportion of patients with whom PCPs discuss CRC testing, and increase the number of
patients who make decision for or against CRC screening.
The outcomes in PCPs of QCs allocated to the intervention group will be compared to those in
the control group. The outcomes will be measured through anonymous structured patient data
collected on 40 consecutive patients by PCPs and questionnaires filled by PCPs.
To ensure that relevant outcomes important for future implementation and dissemination works
are collected, the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM)
framework will be followed for structuring the data collection. The RE-AIM framework helps
structure the collection of data on the characteristics of the participants invited who
finally participate in the study (Reach), on the integration of the planned intervention in
their work (Adoption), on the consistency of implementation of the planned intervention by
study participants (Implementation), on the maintenance of the intervention effects over time
(Maintenance), and finally, on the effectiveness of the intervention on the planned outcomes
(Effectiveness). The RE-AIM criteria are useful for identifying the translatability and
public health impact of this intervention, and for making clear to future stakeholders the
internal and external validity of study results.
This study will test the benefits of a multilevel training program in participatory medicine
designed to help PCPs in Switzerland to better diagnose patient preferences for screening and
method of screening method (colonoscopy or FIT) through. If the program is successful it will
increase the proportion of patients who can decide to undergo testing or not and with which
method. This should increase in number of patients who are screened or intend to be screened
for CRC, and thus reduce CRC deaths in the longer term.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |